Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

and full year 2024 financial results conference call. As a reminder, today's program is being recorded. At this time, I'd like to turn the call over to Mary Jenkins, Associate Director, Investor Relations and Corporate Communications. Please go ahead. Thank you, Lisa, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the fourth quarter and full year 2024. The press release, slides, and supplementary information are available on the investor section of our website at Sarepta.com. Our 10-K will be filed with the SEC later this week. Joining us on the call today are Doug Ingram, Ian Estepan, Dallin Murray, and Dr. Louise Rodino-Klapak. After our formal remarks, we'll open the call for Q&A. I'd like to note that during this call, we were making a number of forward-looking statements. Please refer to slide two on the webcast, which contains our forward-looking statements. These forward-looking statements involve risks and uncertainties, many of which are beyond surreptitious control. Actual results could materially differ from these forward-looking statements, and any such risks can materially and adversely affect the business. The results of operations and trading prices for surreptitious common stock. For a detailed description of applicable risks and uncertainties, we encourage you to review the company's most recent SEC filings. The company does not undertake any obligation to publicly update its forward-looking statements including any financial projections provided today based on subsequent events or circumstances. As noted on slide three, we will discuss non-GAAP financial measures on this webcast. Descriptions of these non-GAAP financial measures and reconciliations of GAAP to non-GAAP are included in today's...